A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
|Videos|December 15, 2015
- Breast Cancer (Issue 2)
- Volume 1
- Issue 2
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Author(s)William Sikov, MD
William Sikov, MD, associate director of Clinical Research, Program in Women
Advertisement
William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.
Articles in this issue
almost 11 years ago
Dr. Carey Anders on Treating Brain Metastases in Breast Canceralmost 11 years ago
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Canceralmost 11 years ago
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Canceralmost 11 years ago
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBCAdvertisement
Related to this article
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durability of PFS and OS Benefit vs. Historical Control
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5